Dec 18, 2017· Comment from Association for Accessible Medicines· FDA-2017-D-5928-0005
Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding Docket FDA-2017-D-5928: Post-Complete Response Letter Meetings Between FDA and ANDA Applicants Under GDUFA.